Live Breaking News & Updates on Breast cancer congress

Stay updated with breaking news from Breast cancer congress. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Truqap/Faslodex Delays Time to Breast Cancer Progression, Next Therapy

Adding Truqap to Faslodex improved outcomes in patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer.

California , United-states , San-francisco , Truqap-faslodex , University-of-california , Drug-administration , Breast-cancer-congress , Department-of-medicine , Cancer-infusion-services , Helen-diller-comprehensive-cancer-center , Breast-oncology , Clinical-trials-education

Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer

Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Texas , United-states , United-kingdom , Houston , Radiopharm-theranostics , Institut-gustave-roussy , Timothya-yap , Eli-lilly , Pfizer , Clinical-development , Cancer-research-united-kingdom , Zenith

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Germany , German , Menarini-stemline , Pierre-fabre , Forschungs-gmb , Pfizer , Amgen , Novartis , Astrazeneca , German-breast-group , Molecular-health , Breast-cancer-congress

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United-states , Porto-alegre , Rio-grande-do-sul , Brazil , America , Astellas-pharma , Bristol-myers-sqiubb , Roche-genentech , Carlos-barrios , Daiichi-sankyo , Abraxis-biosciences , Novartis

Adding Tecentriq to Chemo Did Not Boost TNBC Survival

The addition of Tecentriq to chemotherapy did not improve overall survival in patients with relapsed triple-negative breast cancer.

Singapore , Breast-cancer-congress , National-cancer-center-singapore , Adding-tecentriq ,

Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Berlin , Germany , San-francisco , California , United-states , Department-of-medicine , Helen-diller-comprehensive-cancer-center , Cancer-infusion-services , University-of-california , Breast-cancer-congress , Breast-oncology

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.

Barcelona , Comunidad-autonoma-de-cataluna , Spain , Hebron , Israel-general- , Israel , Daiichi-sankyo-astrazeneca , Mafalda-oliveira , Pfizer , Genentech , Breast-cancer-congress , Novartis

Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.

James-cayne , Komal-jhaveri , Early-drug-development-service , Endocrine-therapy-research-program , Breast-cancer-congress , Cancer-congress , James-cayne-chair , Junior-faculty , Memorial-sloan-kettering-cancer-center ,

Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC

Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

London , City-of , United-kingdom , Peter-schmid , Astrazeneca , Pfizer , Barts-cancer-institute-of-queen-mary-university , Novartis , Breast-cancer-congress , Boehringer-ingelheim , Amgen , Cancer-congress

Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC

Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Singapore , Breast-cancer-congress , National-cancer-center-singapore ,